Americas > North America > United States > US Healthcare Inefficiency: Evidence From International Prescription Drug Data

United States: US Healthcare Inefficiency: Evidence From International Prescription Drug Data

2017/05/29

Despite higher per capita healthcare spending, US health outcomes compare poorly with other developed nations. One potential reason is that the US healthcare system creates incentives that promote the faster adoption of medical technologies with minimal benefits. This column tests this claim using data on the quality and diffusion of new pharmaceuticals in the US and four other nations. The results suggest that compared to Australia, Canada, Switzerland, and the UK, low-quality drugs diffuse additional quickly in the US relative to high-quality drugs.

Although the US spends additional on healthcare per capita than any other developed country, it does not enjoy better health outcomes. Are institutional features of the US healthcare system driving this apparent inefficiency? Garber and Skinner (2008) hypothesised that the fee-for-service system of reimbursement prevalent in the US may create incentives for faster adoption of new medical technologies that may have minimal clinical benefits. However, due testing this hypothesis is generally complicated in part because it is difficult to construct consistent measures of healthcare utilisation across nations in a way that holds quality of care constant. For example, a surgical procedure may be used additional in one country than an extra because the quality of the procedure is higher in that country, not because it is inefficiently administered.

In a recent paper, we argue that the adoption and diffusion of new pharmaceuticals across nations is well-suited for testing the Garber-Skinner conjecture (Kyle and Williams, 2017). Initial, we can be confident that pharmaceutical use is relatively consistently measured across nations – there is little difference between the cancer drug Avastin sold in the US and the cancer drug Avastin sold in other nations. Second, for pharmaceuticals it is possible to exploit an existing measure of drug quality that is based solely on clinical price (that is, this quality measure is independent of the drug’s price). Despite having some limitations, this quality measure allows us to compare whether the US differs from other developed nations in the adoption and diffusion of drugs with relatively high therapeutic price relative to those that provide additional marginal gains.

Data and measures

We analyse quarterly data from 2000-2013 on revenues and quantities sold for new pharmaceuticals in Australia, Canada, Switzerland, and the UK provided by QuintilesIMS Health. We accumulation across all packages or presentations of a drug to the molecule (or molecule combination) level.

For our measure of drug quality, we rely on assessments of France’s Haute Autorité de Sante (HAS). At the same time as a drug is introduced in France, the HAS evaluates both its clinical importance and its relative therapeutic price over existing treatments. The latter, referred to as the ASMR (amélioration du service médical rendu, or development in actual benefit), is a score from I to V. ASMR I corresponds to major improvements. Gleevec, generally considered a breakthrough treatment for some cancers, is an example. ASMR V is assigned to all generic drugs (which offer no clinical benefit relative to the originator version) inclunding other new drugs with no evidence of clinical superiority over existing treatments. The ASMR evaluation takes place before price negotiations in France – it is an assessment of clinical price, not an assessment of cost-effectiveness.1

Our sample is confined to drugs for which an ASMR rating is available and for which we have complete sales data from the time of launch. In addition, we focus on new brand-name or originator products – that is, new molecular or biologic entities – rather than generic drugs. We focus on comparing outcomes in the US to outcomes in four other major developed nations: Australia, Canada, Switzerland, and the UK.2

Results

Our key research question is: how do higher- and lower-quality drugs diffuse over time in the US relative to our comparison nations? We measure diffusion by sales of standard units (that is, by measuring quantities rather than revenues), and focus our quality metric on a comparison of additional (ASMR I/II/III) and less (ASMR IV/V) therapeutically precious drugs. We analyse diffusion over the initial six years next a product is launched, during which time a new product should generally not face any generic competition. We estimate a regression specification that pools all five nations and includes fixed effects for drugs, nations, and years since launch.

Our results suggest that – consistent with the Garber-Skinner conjecture – the US is indeed “uniquely inefficient” in the sense that low-quality drugs diffuse additional quickly compared to high-quality drugs, relative to the comparison nations we analyse. The same pattern holds if we compare the US against each of our comparison nations individually, although the difference in coefficients is only statistically significant in pairwise comparisons at the same time as comparing the US to the UK and to Switzerland. All of these results are strengthened if we omit the ASMR III (‘intermediate’) quality category.

Figures 1-4 provide a graphical summary of our results. In each, we plot the diffusion curves – units sold relative to the initial year of launch in each country – for lower-quality drugs (in dark red) and higher-quality drugs (in light blue), with 95% confidence intervals. While the confidence intervals for low and high quality drugs are overlapping in this additional disaggregated comparison, qualitatively the in general patterns are remarkably consistent – with the exception of the year of and initial year next launch in Australia and Canada, lower-quality drugs consistently diffuse additional in the US relative to higher-quality drugs, judged relative to any of the four comparison nations.

Conclusion

Prior work (Kyle 2007, Kyle and Qian 2014, and Cockburn et al. 2016) has attempted to quantify the influence of factors such as intellectual property rights and price control policies on firms’ decisions to launch new drugs globally. To the best of our knowledge, our paper is the initial to focus on how diffusion varies across nations based on a measure of therapeutic quality. While our drug quality measure is of course imperfect – in particular, while it is independent of price, assignment of these measures happens in the shadow of price negotiations – it arguably takes a step forward in considerate the welfare implications of cross-country differences in drug diffusion.

Our tabulations suggest that low-quality drugs diffuse additional quickly compared to high quality drugs in the US relative to these four comparison nations. These patterns are consistent with the assertion in Gruber and Skinner (2008) that the US healthcare system may be “uniquely inefficient” in the sense of fuelling the rapid adoption and diffusion of medical technologies with small or unknown benefits.

Our hope is that, someday, the newly linked data developed in our paper can be combined with an analysis of policy changes in order to analyse the potential roles of specific factors in explaining the higher diffusion of lower quality drugs in the US relative to other nations. For example, does the use of centralised health technology assessments in nations outside the US encourage the adoption of technologies with higher measured benefits? What are the longer-term consequences of such policies, not only for health spending but as well for health outcomes?

Related Articles
  • Kenya Airways Gets Permit For Direct U.S. Flights

    2017/09/11 The United States government has granted Kenya Airways a permit to operate direct flights to America. According to an order issued by the Department of Transportation, the permit became effective on September 5. The Department of Transportation had in June recommended that KQ, as the airline is commonly known, be granted the permit if there were no public objections.
  • UNWTO: International tourism – strongest half-year results since 2010

    2017/09/09 Destinations worldwide welcomed 598 million international tourists in the initial six months of 2017, some 36 million additional than in the same period of 2016. At 6%, increase was well above the trend of recent years, making the current January-June period the strongest half-year since 2010. Visitor numbers reported by destinations around the world reflect strong request for international travel in the initial half of 2017, according to the new UNWTO World Tourism Barometer. Worldwide, international tourist arrivals (overnight visitors) increased by 6% compared to the same six-month period last year, well above the sustained and consistent trend of 4% or higher increase since 2010. This represents the strongest half-year in seven years.
  • Not a choice for some tourists and residents

    2017/09/09 St. Petersburg, Florida, has been voted to have the nicest white sandy beaches in the United States, and along with the rest of Florida, this thriving tourism destination on Tampa Bay is in for a nightmare at the same time as Hurricane Irma hits at category 3 or 4 strength. The massive hurricane that has been barreling through the Caribbean, is expected to run up the east coast of Florida, which would mean tropical storm conditions along the west coast on Sunday. However, the bay area remains just inside the cone of uncertainty.
  • Saudi King to visit White House in 2018

    2017/09/08 King Salman of Saudi Arabia will make an official visit to Washington early next year for talks with President Donald Trump, the White Home said Wednesday. King Salman and President Trump discussed how to advance shared goals such as strengthening security and prosperity in the Middle East The two leaders held a telephone conversation in which they discussed how to advance shared goals such as strengthening security and prosperity in the Middle East, the White Home said in a statement.
  • Spotify, Hulu target students with discounted bundle

    2017/09/08 U.S. college students can buy Spotify Premium music streaming and Hulu TV streaming for a combined, deeply discounted $4.99 per month, in a new student subscription bundle the companies announced on Thursday to lure younger consumers. The entertainment bundle, $13 cheaper than the regular combined price, is the new effort in the industry to gain young millennial customers, who favor inexpensive online streaming and listening.